The Medicines Co. Newsletter
-
Dazed Mix: Jennifer Walton
31 Oct 2025 01:36 GMT
… , panic attacks / From my medicines co-pay / I’m Miss …
-
Biomea Fusion to Present Poster Presentations at ObesityWeek®2025
30 Oct 2025 12:00 GMT
… clinical-stage diabetes and obesity medicines company, today announced that it will … clinical-stage diabetes and obesity medicines company focused on the development of …
-
Blacksmith Medicines Co-Founder Presents At The 21St International Conference On Biological Inorganic Chemistry
01 Aug 2025 17:10 GMT
(MENAFN- PR Newswire)
Presentation highlights Blacksmith's novel chemistry platform for targeting metalloenzymes and FG-2101, a first-in-class non-hydroxamate LpxC inhibitor
SAN DIEGO, Aug. 1, 2025 /PRNewswire/ -- Blacksmith Medicines, Inc. ( …
-
KFSHRC and Novartis Sign MoU to Advance Clinical Research, Patient Care, and Access to Innovative Therapies
29 Oct 2025 17:55 GMT
… (KFSHRC) and Novartis, an innovative medicines company, signed a Memorandum of Understanding … Novartis
Novartis is an innovative medicines company. Every day, we work to …
-
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025
29 Oct 2025 00:50 GMT
… : ARCT), a commercial messenger RNA medicines company focused on the development of …
-
SparingVision Doses First Patient with SPVN20 for Advanced Retinitis Pigmentosa in NYRVANA Trial
28 Oct 2025 12:00 GMT
… is a clinical-stage genomic medicines company with a mission to translate …
-
Novartis Delivers Solid Sales And Core Operating Income Growth With Strong Pipeline Progress In Q3 Reaffirms FY 2025 Guidance
28 Oct 2025 07:26 GMT
… is a“pure-play” innovative medicines company. We have a clear focus … Novartis
Novartis is an innovative medicines company. Every day, we work to …
-
Novartis Continues RNA & Neuroscience Growth Strategy With $12B Avidity Bio Acquisition
28 Oct 2025 05:09 GMT
… pharma giant followed its The Medicines Company acquisition with the 2023 purchase …
-
Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
27 Oct 2025 12:00 GMT
… clinical-stage diabetes and obesity medicines company, today announced that the first … clinical-stage diabetes and obesity medicines company focused on the development of …
-
Novartis makes $12bn wager on RNA drugs with Avidity buy
27 Oct 2025 10:58 GMT
… .7 billion takeover of The Medicines Company in 2019 and $8.7 …